Job description:
Join Us in Changing Lives
AtOXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day:Responsible, Responsive, Resilient, and Respectful.
We’re currently recruiting for aVP, Head of Site Services. In this role, you will lead, inspire and manage the strategic and operational performance of OXB UK site services functions on the Oxford Site to ensure high quality, compliant, timely and efficient services are provided to support all site activities. Site Service functions include Engineering, Facilities Management, Validation, and Safety, Health and Environment (SHE).
The role works as a key member of the UK Site Leadership team to deliver a high quality, efficient, client-centric service, with a focus on delivery. The team works closely together to overcome challenges and manage resources according to specific needs of the business, playing a key part in advancing our mission and making a real difference.
Your responsibilities in this role would be:
* Active Member of the Oxford Site Leadership Team
* Leading and inspiring a team of professionals, coaching and developing capability and competency within the team and ensuring effective management processes are in place to manage and recognise performance.
* Budgetary control, maintain and manage to budget. Work alongside the Procurement Team to drive savings and improve cost control
* Exemplify the OXB values of Responsible, Responsive, Resilient and Respect. Define and implement site, regulatory and corporate guidelines, policies, procedures and industry standards to ensure ongoing compliance of all service function team activities.
* Define the departmental structure ensuring optimal resources are in place for the cost-effective delivery of requirements. Use lean principles to drive safety, efficiency, quality and delivery.
* Set individual & team objectives, and performance manage to ensure ownership and delivery
* Ensure all GMP processes, systems (including computer systems) and equipment are validated in line with cGMP and includes a robust Science Risk based approach.
* Active member of Global Environment, Social, Environment (ESG) Group, to drive and integrate sustainable and ethical practices within the business whilst leading local site-based activities
* Agree and deliver against service levels required from site services to support other Site functions. Provide leadership across the site services functions (Engineering, Facilities, Validation and SHE) to:
o Deliver CAPEX, engineering and facility projects
o Ensure a safe and compliant working environment for all Oxford UK staff
o Deliver Facilities services across Oxford sites as per appropriate service level agreements
* Ownership of UK Business Continuity, and Environmental performance plans
We are Looking For:
* Degree level qualified in a scientific or technical discipline
* Management experience in a highly regulated Biotech or Pharma environment, experience in engineering in a cGMP environment
* Skilled at using data to drive decision making.
* Be a change agent for the department and site.
* Drive safety, quality and project risk.
* Instils a culture of ownership and Continuous Improvement.
* Core competency in Lean/Operational Excellence. Driving Safety, Quality, Delivery and cost.
* Experience of implementing new computerized maintenance management systems
* Knowledge of the financial aspects of the business, including budget control, budget planning, as well as impact of cost on COGS.
* Demonstrates excellent judgment, mental agility and problem-solving skills, uses commercial acumen, strategic and big picture thinking to drive the business forward.
* Strong understanding of Validation Lifecycle, Engineering, Maintenance, Facilities management and Security.
About Us:
OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies.
OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.
Why Join Us?
* 💸Competitive total reward packages
* 🧘Wellbeing programmes that support your mental and physical health
* 🚀Career development opportunities to help you grow and thrive
* 🤝Supportive, inclusive, and collaborative culture
* 🧪State-of-the-art labs and manufacturing facilities
* 🌍 A company that lives its values:Responsible, Responsive, Resilient, Respect
Ready to Make a Difference?
Collaborate. Contribute. Change lives.
We offer:
* Competitive total reward packages
* Wellbeing programmes that support your mental and physical health
* Career development opportunities to help you grow and thrive
* Supportive, inclusive, and collaborative culture
* State-of-the-art labs and manufacturing facilities
* A company that lives its values:Responsible, Responsive, Resilient, Respect
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.
#J-18808-Ljbffr